Qilu Pharmaceutical Co., Ltd. China

Results from the Clinical Trial of Qilu Pharmaceutical's Novel Anticancer Agent Iparomlimab and Tuvonralimab Featured in Oral Presentation at the ESGO Annual Meeting

View original content:https://www.prnewswire.co.uk/news-releases/results-from-the-clinical-trial-of-qilu-pharmaceuticals-novel-anticancer-agent-iparomlimab-and-tuvonralimab-ql1706-featured-in-oral-presentation-at-the-esgo-annual-meeting-302078257.html